Clinical Study
Lithium Carbonate in the Treatment of Graves’ Disease with ATD-Induced Hepatic Injury or Leukopenia
Table 2
Therapeutic measures for GD with hepatic injury and GD with leukopenia.
| | | GD with hepatic injury | GD with leukopenia |
| | Patients (male/female), | 33 (5/28) | 18 (3/15) | | Lithium carbonate (%) | | | | 50 mg/day | 7 (21) | 5 (28) | | 75 mg/day | 26 (79) | 13 (72) | | Hepatoprotective (%) | | | | Diammonium Glycyrrhizinate | 22 (67) | 0 | | Polyene Phosphatidylcholine | 16 (48) | 0 | | Leucocyte drug (%) | | | | Leucogen | 0 | 16 (89) | | GCSF | 0 | 3 (17) | | Glucocorticoids (%) | | | | Prednisone | 9 (27) | 5 (28) | | Methylprednisolone | 3 (9) | 2 (11) | | Propranolol (%) | 32 (97) | 16 (89) |
|
|
Data were expressed as percentage of the total.
|
